Organon & Co.
OGNHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 7, 2026
Scan Results
Daily timeframeOrganon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle. At a $3.62B market cap, Organon & Co. ranks as a mid-cap company within healthcare. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.
Market Cap
$3.62B
Beta
1.52
P/E (TTM)
17.67
P/E (Fwd)
3.81
EPS (TTM)
$0.78
EPS (Fwd)
$3.62
ROE
24.0%
ROA
5.7%
Cash
$1.13B
Total Debt
$8.55B
Free CF
$490.8M
52W Change
31.6%
Annual Financials
Cash vs Debt
Where OGN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OGN finished 24.84% above its 150-day moving average ($11.03) and 35.13% above its 200-day moving average ($10.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OGN overbought or oversold?
At the September 3, 2026 close, OGN's RSI(14) was 70.6, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Organon & Co. carries $8.55B in total debt against $1.13B in cash reserves — debt is roughly 7.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $490.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 24.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $6.17B (2022) to $6.22B (2025).
Organon & Co.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Organon & Co. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OGN.